## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.75)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. New York State Common Retirement Fund Sells 15,100 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251130T123758 | Somewhat-Bullish | Relevance: 99%
- The New York State Common Retirement Fund reduced its stake in Gilead Sciences, Inc. by 1.0%, selling 15,100 shares, but still holds 1,562,317 shares valued at $173.2 million. The company reported strong Q3 earnings, beating analyst expectations, and declared a quarterly dividend of $0.79. Despite recent insider selling, analysts maintain a "Moderate Buy" rating with a consensus target price of $130.65.

**2. Panagora Asset Management Inc. Has $175.96 Million Stock Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251202T123113 | Bullish | Relevance: 99%
- Panagora Asset Management Inc. reduced its stake in Gilead Sciences by 2.1% but still holds a significant position valued at $175.96 million. The article details institutional ownership changes, recent financial performance including beating EPS and revenue estimates, and analyst ratings which average a "Moderate Buy" with a target price of $130.65.

**3. Gilead Sciences (NASDAQ:GILD) CEO Sells $1,265,400.00 in Stock**
- Source: MarketBeat | 20251202T232225 | Somewhat-Bullish | Relevance: 99%
- Gilead Sciences CEO Daniel Patrick O'day sold 10,000 shares of company stock for $1,265,400 on November 28, reducing his stake by 1.72%. This follows similar sales in October and September, indicating a pattern of insider selling. The company recently reported beating Q3 earnings and revenue estimates and declared a quarterly dividend.

**4. Gifford Fong Associates Sells 25,000 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251201T095233 | Somewhat-Bullish | Relevance: 99%
- Gifford Fong Associates significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by selling 25,000 shares in the second quarter, retaining 9,000 shares valued at approximately $998,000. This follows recent insider selling by the CFO and CEO. Despite the share sales, Gilead Sciences has reported strong quarterly earnings, beating analyst estimates, and provided positive FY2025 guidance, with analysts largely maintaining a "Moderate Buy" rating.

**5. Scotia Capital Inc. Sells 17,090 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251130T122136 | Somewhat-Bullish | Relevance: 99%
- Scotia Capital Inc. trimmed its stake in Gilead Sciences (NASDAQ:GILD) by 11.2% in the second quarter, selling 17,090 shares and holding 135,068 shares valued at $14.98 million. This comes as Gilead reported strong quarterly earnings, beat revenue expectations, and issued upbeat FY 2025 guidance, leading to several analyst price target increases and a "Moderate Buy" consensus rating.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $7.1M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 14.2x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.6B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 14.2 |
| Current P/E | 15.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.3% to -4.1% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >3.0% for momentum thesis). Underperforming sector by 3.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.13% (CS: 11) | Weak |
| RSI_14 | 51.3 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.91
- **Stop Loss:** $117.75 (5.0% risk)
- **Target:** $130.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 162
- **Position Value:** $20,073.42
- **Portfolio %:** 20.07%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*